Paul and Treating a Source

GRAPHIC:
[10-SECOND COUNTDOWN BEGINS]

On-screen text:
Skyrizi®
risankizumab-rzaa

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

SAFETY CONSIDERATIONS

SKYRIZI may cause serious side effects, including:

• Serious allergic reactions: Stop using SKYRIZI and get emergency medical help right away if you get any symptoms of a serious allergic reaction.


• Infections: SKYRIZI may increase your risk of infections. Before starting treatment, your doctor should check you for infections and tuberculosis. Tell your doctor right away if you have an infection or symptoms of one.

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI.

Also, tell your doctor if you plan to or recently received a vaccine.

Please see additional Important Safety Information near the end of this video. Please see link for the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

On-screen text:
[Paul's signature]
PAUL, A SKYRIZI PATIENT

Paul (V.O.):
My name is Paul and I have moderate to severe plaque psoriasis.

Paul (V.O.):
I tried ointments, creams, lotions, tanning booths, holistic medicines and stuff like that and it wasn’t making a difference.

Paul (V.O.):
My forearms, my elbows, my knees, my shins, above my eyebrows, it was terrible.

Paul (V.O.):
I finally found a doctor who put me in touch with an injectable, Humira.

On-screen text:
HUMIRA® (adalimumab) is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

Paul (V.O.):
When I was on Humira, like I said, I'd see patches and I thought, well, you know, this is good enough, this is better than it was, and it’s, it’s working for me.

On-screen text:

Paul (V.O.):
I was content with where I was.

Paul (V.O.):
When I moved to Florida from Massachusetts, I got a new dermatologist.

Paul (V.O.):
And my whole idea was that I'd go in, meet this new dermatologist and say, look, the Humira’s working for me; I just need a refill on my prescription.

On-screen text:
In a clinical study of 605 patients, MORE PEOPLE ON SKYRIZI ACHIEVED 90% CLEARER SKIN than those on HUMIRA at week 16.

On-screen text:
72% of patients achieved 90% clearer skin on SKYRIZI vs. 47% of those on HUMIRA.

Paul (V.O.):
And she piqued my interest when she said, there’s this new treatment out there, SKYRIZI, and it might work a little better for you.

On-screen text:
At 16 weeks, some HUMIRA patients were switched to SKYRIZI*
OF THOSE WHO SWITCHED FROM HUMIRA TO SKYRIZI,
3x MORE PEOPLE ACHIEVED
90% CLEARER SKIN AT WEEK 44.

*At week 16, 109 HUMIRA patients who had at least 50% but less than 90% clearer skin were either switched to SKYRIZI for 28 more weeks, or stayed on HUMIRA through the remainder of the study, a total of 44 weeks. 66% of patients achieved 90% clearer skin on SKYRIZI vs. 21% of those on HUMIRA.

Paul (V.O.):
The amount of time between my first injection with SKYRIZI to the time that I noticed that my flaking had almost ceased was amazing.

On-screen text:
In clinical trials, 3 out of 4 people achieved 90% clearer skin at 4 months, after just 2 doses.

On-screen text:
I’m definitely between 90% and 98%.

Paul (V.O):
I’m definitely between 90 and 98%.

Paul (V.O.):
I was psoriasis first, Paul second. And now I'm, you know, I'm Paul and I just happen to have psoriasis.

On-screen text:
I’m Paul and I just happen to have psoriasis.

V.O./On-screen text:

USE AND IMPORTANT SAFETY INFORMATION

SKYRIZI^® (risankizumab-rzaa) USE

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

Important Safety Information

What is the most important information I should know about SKYRIZI ^® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including: 

Serious allergic reactions: 

• Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
  - fainting, dizziness, feeling lightheaded (low blood pressure)
  - swelling of your face, eyelids, lips, mouth, tongue, or throat
  - trouble breathing or throat tightness
  - chest tightness
  - skin rash, hives
  - itching

Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

• Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
  - fever, sweats, or chills
  - cough
  - shortness of breath
  - blood in your mucus (phlegm)
  - muscle aches
  - warm, red, or painful skin or sores on your body different from  your psoriasis
  - weight loss
  - diarrhea or stomach pain
  - burning when you urinate or urinating more often than normal
  

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. 

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”
• have an infection that does not go away or that keeps coming back.
• have TB or have been in close contact with someone with TB.
• have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
• become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

The most common side effects of SKYRIZI include upper respiratory infections, feeling tired, fungal skin infections, headache, and injection site reactions.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.

On-screen Text:
Skyrizi®
risankizumab-rzza

abbvie